Pediatric malignant gliomas are rare, aggressive brain tumors with limited treatment options and poor outcomes, where current standards of care—including surgery and radiation—often fail to prevent ...
Plus Therapeutics Inc. PSTV shares are up on Friday on continuous momentum after the company announced that the U.S. Food and ...
Plus Therapeutics Inc. (NASDAQ:PSTV) said the U.S. Food and Drug Administration has granted Orphan Drug Designation to ...
FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.
- Designation Underscores the Significant Unmet Medical Need as AMXT 1501 Advances in Two Active National Clinical Trials — Including a Pediatric Study Now Enrolling Children with DIPG SEATTLE, March ...
Malignant gliomas are among the deadliest brain cancers, with limited treatment options and poor survival. A new comprehensive review analyzes decades of global clinical data on boron neutron capture ...
A water-soluble, luminescent europium complex enables evaluation of malignancy grade in model glioma tumor cells. An important part of choosing the most suitable cancer therapy is understanding the ...
Collaborating researchers led by a team at Hokkaido University have developed a non-destructive cancer grade probing system (GPS) that uses a water-soluble, luminescent europium (EuIII) complex to ...
Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study Antivascular endothelial ...
Annual incidence rate of developing a primary malignant brain tumor is 7/100,000n population, and the lifetime risk is 0.6 percent. In addition, metastases from systemic cancer to the brain are 10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results